Skip to main content

Compare Stocks

Date Range: 

 Profound MedicalCytosorbentsUFP TechnologiesAcutus MedicalClearPoint Neuro
SymbolNASDAQ:PROFNASDAQ:CTSONASDAQ:UFPTNASDAQ:AFIBNASDAQ:CLPT
Price Information
Current Price$17.30$8.14$55.52$13.33$18.08
52 Week RangeBuyBuyBuyHoldBuy
MarketRank™
Overall Score1.71.71.31.31.4
Analysis Score3.63.50.03.13.5
Community Score3.63.52.41.33.5
Dividend Score0.00.00.00.00.0
Ownership Score0.80.81.71.70.0
Earnings & Valuation Score0.60.62.50.60.0
Analyst Ratings
Consensus RecommendationBuyBuyBuyHoldBuy
Consensus Price Target$29.67$15.67N/A$24.80$35.00
% Upside from Price Target71.48% upside92.47% upsideN/A86.05% upside93.58% upside
Trade Information
Market Cap$342.12 million$352.18 million$417.90 million$343.38 million$357.95 million
Beta1.450.360.92N/A1.15
Average Volume80,270325,70129,154336,778429,597
Sales & Book Value
Annual Revenue$4.17 million$24.95 million$198.38 million$2.84 million$11.22 million
Price / Sales84.3814.132.11132.0033.05
CashflowN/AN/A$4.27 per shareN/AN/A
Price / CashN/AN/A12.99N/AN/A
Book Value$0.92 per share$0.11 per share$21.78 per shareN/A$0.30 per share
Price / Book18.8074.002.5560.27
Profitability
Net Income$-15,220,000.00$-19,270,000.00$19.75 million$-97,040,000.00$-5,540,000.00
EPS($1.37)($0.60)$2.63N/A($0.42)
Trailing P/E RatioN/AN/A27.760.00N/A
Forward P/E RatioN/AN/A21.44N/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-275.12%-30.45%8.12%-1,410.17%-55.55%
Return on Equity (ROE)-33.69%-34.37%8.94%N/A-309.91%
Return on Assets (ROA)-29.34%-19.74%7.67%-74.36%-34.06%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A0.07%N/A0.25%118.51%
Current Ratio28.03%5.58%4.27%10.89%5.42%
Quick Ratio26.53%5.46%3.06%10.21%4.47%
Ownership Information
Institutional Ownership Percentage35.90%39.83%76.06%69.56%6.61%
Insider Ownership PercentageN/A5.70%11.00%N/A9.15%
Miscellaneous
Employees10919586029167
Shares Outstanding20.34 million43.32 million7.53 million28.12 million20.51 million
Next Earnings Date8/5/2021 (Estimated)8/3/2021 (Estimated)8/3/2021 (Estimated)9/16/2021 (Estimated)8/11/2021 (Estimated)
OptionableOptionableOptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
ClearPoint Neuro, Inc. Expected to Earn Q4 2021 Earnings of ($0.11) Per Share (NASDAQ:CLPT)ClearPoint Neuro, Inc. Expected to Earn Q4 2021 Earnings of ($0.11) Per Share (NASDAQ:CLPT)
americanbankingnews.com - May 14 at 10:16 AM
US$35.00 - Thats What Analysts Think ClearPoint Neuro, Inc. (NASDAQ:CLPT) Is Worth After These ResultsUS$35.00 - That's What Analysts Think ClearPoint Neuro, Inc. (NASDAQ:CLPT) Is Worth After These Results
finance.yahoo.com - May 13 at 9:23 AM
Comparing STRATA Skin Sciences (NASDAQ:SSKN) & ClearPoint Neuro (NASDAQ:CLPT)Comparing STRATA Skin Sciences (NASDAQ:SSKN) & ClearPoint Neuro (NASDAQ:CLPT)
americanbankingnews.com - May 12 at 3:18 PM
ClearPoint Neuro (NASDAQ:CLPT) Releases FY 2021 Earnings GuidanceClearPoint Neuro (NASDAQ:CLPT) Releases FY 2021 Earnings Guidance
americanbankingnews.com - May 12 at 1:48 PM
ClearPoint Neuro, Inc. (CLPT)ClearPoint Neuro, Inc. (CLPT)
finance.yahoo.com - May 12 at 12:35 PM
ClearPoint Neuro (NASDAQ:CLPT) Posts  Earnings Results, Beats Expectations By $0.02 EPSClearPoint Neuro (NASDAQ:CLPT) Posts Earnings Results, Beats Expectations By $0.02 EPS
americanbankingnews.com - May 12 at 12:24 PM
ClearPoint Neuro, Inc. (CLPT) Q1 2021 Earnings Call TranscriptClearPoint Neuro, Inc. (CLPT) Q1 2021 Earnings Call Transcript
fool.com - May 12 at 1:46 AM
ClearPoint Neuro: Q1 Earnings InsightsClearPoint Neuro: Q1 Earnings Insights
benzinga.com - May 11 at 9:22 PM
ClearPoint Neuro Reports Record Revenue in First Quarter 2021 Results, Announces FDA Clearance ...ClearPoint Neuro Reports Record Revenue in First Quarter 2021 Results, Announces FDA Clearance ...
apnews.com - May 11 at 4:22 PM
ClearPoint Neuro Reports Record Revenue in First Quarter 2021 Results, Announces FDA Clearance of the SmartFrame ‘Array’ClearPoint Neuro Reports Record Revenue in First Quarter 2021 Results, Announces FDA Clearance of the SmartFrame ‘Array’
finance.yahoo.com - May 11 at 4:22 PM
ClearPoint Neuro Announces Partnership With D&K Engineering for Development of Robotic ...ClearPoint Neuro Announces Partnership With D&K Engineering for Development of Robotic ...
apnews.com - May 11 at 11:22 AM
ClearPoint Neuro Announces Partnership With D&K Engineering for Development of Robotic System for the MRI Suite and Operating RoomClearPoint Neuro Announces Partnership With D&K Engineering for Development of Robotic System for the MRI Suite and Operating Room
finance.yahoo.com - May 10 at 7:00 PM
ClearPoint Neuro Stock Is Estimated To Be Significantly OvervaluedClearPoint Neuro Stock Is Estimated To Be Significantly Overvalued
news.yahoo.com - May 8 at 7:12 PM
Earnings Preview: ClearPoint Neuro, Inc. (CLPT) Q1 Earnings Expected to DeclineEarnings Preview: ClearPoint Neuro, Inc. (CLPT) Q1 Earnings Expected to Decline
finance.yahoo.com - May 4 at 8:24 PM
ClearPoint Neuro (CLPT) to Release Earnings on TuesdayClearPoint Neuro (CLPT) to Release Earnings on Tuesday
americanbankingnews.com - May 4 at 10:38 AM
ClearPoint Neuro (NASDAQ:CLPT) & Accuray (NASDAQ:ARAY) Critical SurveyClearPoint Neuro (NASDAQ:CLPT) & Accuray (NASDAQ:ARAY) Critical Survey
americanbankingnews.com - May 4 at 6:22 AM
Short Interest in ClearPoint Neuro, Inc. (NASDAQ:CLPT) Rises By 23.9%Short Interest in ClearPoint Neuro, Inc. (NASDAQ:CLPT) Rises By 23.9%
americanbankingnews.com - May 4 at 3:46 AM
ClearPoint Neuro to Announce First Quarter 2021 Results May 11, 2021ClearPoint Neuro to Announce First Quarter 2021 Results May 11, 2021
finance.yahoo.com - April 29 at 7:45 PM
ClearPoint Neuro, Inc. Congratulates Voyager Therapeutics on FDA Clearance of IND Application for Gene Therapy Candidate VY-HTT01 for Treatment of Huntington’s DiseaseClearPoint Neuro, Inc. Congratulates Voyager Therapeutics on FDA Clearance of IND Application for Gene Therapy Candidate VY-HTT01 for Treatment of Huntington’s Disease
finance.yahoo.com - April 28 at 5:08 PM
ClearPoint Neuro, Inc. (NASDAQ:CLPT): When Will It Breakeven?ClearPoint Neuro, Inc. (NASDAQ:CLPT): When Will It Breakeven?
finance.yahoo.com - April 26 at 12:37 PM
ClearPoint Neuro Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)ClearPoint Neuro Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
finance.yahoo.com - April 23 at 7:50 PM
Analysts Expect Breakeven For ClearPoint Neuro, Inc. (NASDAQ:CLPT) Before LongAnalysts Expect Breakeven For ClearPoint Neuro, Inc. (NASDAQ:CLPT) Before Long
nasdaq.com - April 14 at 12:30 AM
ClearPoint Neuro, Inc. Announces Retirement of Director John N. Spencer, Jr.ClearPoint Neuro, Inc. Announces Retirement of Director John N. Spencer, Jr.
finance.yahoo.com - April 13 at 7:30 PM
ClearPoint Neuro, Inc. Congratulates uniQure on Completion of Enrollment in First Cohort of ...ClearPoint Neuro, Inc. Congratulates uniQure on Completion of Enrollment in First Cohort of ...
apnews.com - April 7 at 2:04 AM
ClearPoint Neuro, Inc. Congratulates uniQure on Completion of Enrollment in First Cohort of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s DiseaseClearPoint Neuro, Inc. Congratulates uniQure on Completion of Enrollment in First Cohort of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
finance.yahoo.com - April 6 at 8:57 PM
DateCompanyBrokerageAction
5/13/2021Profound MedicalAlliance Global PartnersLower Price Target
5/10/2021Profound MedicalRaymond JamesSet Price Target
3/4/2021Profound MedicalLeede Jones GabReiterated Rating
1/25/2021Profound MedicalLake Street CapitalBoost Price Target
9/15/2020Profound MedicalJefferies Financial GroupInitiated Coverage
4/7/2020Profound MedicalMackieDowngrade
4/1/2020Profound MedicalCowenInitiated Coverage
11/8/2019Profound MedicalEchelon Wealth PartnersReiterated Rating
1/4/2021CytosorbentsB. RileyBoost Price Target
9/1/2020CytosorbentsSVB LeerinkInitiated Coverage
5/7/2020CytosorbentsMaxim GroupInitiated Coverage
5/6/2020CytosorbentsHC WainwrightBoost Price Target
3/9/2020CytosorbentsDawson JamesReiterated Rating
12/3/2020UFP TechnologiesSidotiInitiated Coverage
9/1/2020UFP TechnologiesTaglich BrothersReiterated Rating
3/25/2021Acutus MedicalJPMorgan Chase & Co.Reiterated Rating
3/25/2021Acutus MedicalWilliam BlairReiterated Rating
3/25/2021Acutus MedicalCanaccord GenuityLower Price Target
1/14/2021Acutus MedicalBank of AmericaDowngrade
9/17/2020Acutus MedicalBTIG ResearchReiterated Rating
3/12/2020ClearPoint NeuroBrookline Capital ManagementInitiated Coverage
(Data available from 5/14/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.